September 18, 2017 We issued a report on Nabriva Therapeutics (NASDAQ: NBRV) on 8-30-17 at $9.56 due to bullish patterns,
James Goldberg
VP / Corporate Strategy at WOPR Artificial Intelligence and Big Data Predictive Stock Analysis
September 18, 2017
We issued a report on Nabriva Therapeutics (NASDAQ: NBRV) on 8-30-17 at $9.56 due to bullish patterns, a short squeeze starting and undervaluation. The stock is up +35% to $12.95 and has exceed our full valuation price target. It is the #1 gainer in the US today after releasing positive trial results. Take profits now.
https://www.woprresearch.com/freereports2/nbrv20170830.pdf
Artificial Intelligence is a technology that uses machine intelligence and human like thinking ability to process historical and real-time data to make predictions, recommendations, and decisions. AI is not a single technology but a convergence of various technologies, statistical models, algorithms, and approaches. We have spent 18 years developing 11 categories of strategies that dynamically generate predictive research reports when multiple strategies line up at the same time in the same direction, with no conflicting strategies present.
Our founder and CEO has been on CNBC TV, BLOOMBERG TV, BNN TV, and published in PC Artificial Intelligence along with the Wall Street Journal, Dow Jones, CBS MarketWatch, Equities Magazine, SFO Magazine, Technical Analysis of Stocks and Commodities Magazine, Red Herring, MSNBC and has been an approved research analyst for Investor’s Business Daily. Mr. Ronk reached the Top 15 players (out of nearly 600,000 contestants) during CNBC’s Million Dollar Portfolio Challenge.
He was just awarded a 10 year GOLD MEDAL for beating all mutual fund managers over the past 10 years. This was all done USING THE TECHNOLOGY described in this email.